Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

Chemotherapy Improved Pulmonary Arterial Hypertension in a Patient with Chronic-Active Epstein-Barr Virus Infection.

Akagi S, Miki T, Sando Y, Fujii N, Sarashina T, Nakamura K, Ito H.

Int Heart J. 2020 Jan 17. doi: 10.1536/ihj.19-419. [Epub ahead of print]

2.

Liver transplantation in a patient with hereditary haemorrhagic telangiectasia and pulmonary hypertension.

Ejiri K, Akagi S, Nakamura K, Amioka N, Ichikawa K, Yagi T, Ito H.

Pulm Circ. 2019 Dec 18;9(4):2045894019896677. doi: 10.1177/2045894019896677. eCollection 2019 Oct-Dec.

3.

Marked Reduction of Pulmonary Artery Pressure After Registration for Lung Transplantation Is Associated With Long-Term Survival in Patients With Pulmonary Arterial Hypertension - Cohort Study.

Akagi S, Matsubara H, Nakamura K, Oto T, Ejiri K, Ito H.

Circ J. 2020 Jan 24;84(2):245-251. doi: 10.1253/circj.CJ-19-0784. Epub 2019 Dec 21.

4.

Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension.

Nakamura K, Akagi S, Ejiri K, Yoshida M, Miyoshi T, Toh N, Nakagawa K, Takaya Y, Matsubara H, Ito H.

Int J Mol Sci. 2019 Nov 23;20(23). pii: E5885. doi: 10.3390/ijms20235885. Review.

5.

Low Consultation Rate of General Population with Atrial Fibrillation.

Matsumi H, Nakamura K, Eguchi E, Miyoshi T, Nakagawa K, Nishii N, Watanabe A, Ueoka A, Yoshida M, Tokunaga N, Amioka N, Yamada N, Saito D, Morita H, Ogino K, Ito H; Ibara-AF Investigators.

Int Heart J. 2019 Nov 30;60(6):1303-1307. doi: 10.1536/ihj.19-062. Epub 2019 Nov 15.

6.

A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.

Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K.

Circ J. 2019 Dec 25;84(1):15-17. doi: 10.1253/circj.CJ-19-0811. Epub 2019 Nov 16.

7.

Efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with atrial septal defect: a comparison with transcatheter closure alone.

Nakagawa K, Akagi T, Nagase S, Takaya Y, Kijima Y, Toh N, Watanabe A, Nishii N, Nakamura K, Morita H, Kusano K, Ito H.

Europace. 2019 Nov 1;21(11):1663-1669. doi: 10.1093/europace/euz207.

PMID:
31410454
8.

Prognosis after lead extraction in patients with cardiac implantable electronic devices infection: Comparison of lead-related infective endocarditis with pocket infection in a Japanese single-center experience.

Nishii N, Morimoto Y, Miyoshi A, Tsukuda S, Miyamoto M, Kawada S, Nakagawa K, Watanabe A, Nakamura K, Morita H, Morimatsu H, Kusano N, Kasahara S, Shoda M, Ito H.

J Arrhythm. 2019 Jun 28;35(4):654-663. doi: 10.1002/joa3.12164. eCollection 2019 Aug.

9.

Unprecedented crisis-Heart failure hospitalizations in current or future Japan.

Ejiri K, Noriyasu T, Nakamura K, Ito H.

J Cardiol. 2019 Nov;74(5):426-427. doi: 10.1016/j.jjcc.2019.05.006. Epub 2019 Jun 26. No abstract available.

PMID:
31255459
10.

Emerging Role of Coronary Computed Tomography Angiography in Lipid-Lowering Therapy: a Bridge to Image-Guided Personalized Medicine.

Miyoshi T, Osawa K, Ichikawa K, Suruga K, Miki T, Yoshida M, Nakagawa K, Toda H, Nakamura K, Morita H, Ito H.

Curr Cardiol Rep. 2019 Jun 21;21(8):72. doi: 10.1007/s11886-019-1170-4. Review.

PMID:
31228004
11.

Successful radiofrequency catheter ablation of a premature ventricular contraction triggering ventricular fibrillation in a patient with short QT syndrome.

Morimoto Y, Watanabe A, Morita H, Nishii N, Nakamura K, Ito H.

HeartRhythm Case Rep. 2019 Jan 30;5(5):262-265. doi: 10.1016/j.hrcr.2019.01.012. eCollection 2019 May. No abstract available.

12.

A Low Critical Event Rate Despite a High Abnormal Event Rate in Patients with Cardiac Implantable Electric Devices Followed Up by Remote Monitoring.

Morimoto Y, Nishii N, Tsukuda S, Kawada S, Miyamoto M, Miyoshi A, Nakagawa K, Watanabe A, Nakamura K, Morita H, Ito H.

Intern Med. 2019 Aug 15;58(16):2333-2340. doi: 10.2169/internalmedicine.1905-18. Epub 2019 May 22.

13.

Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.

Kimura T, Nakamura K, Miyoshi T, Yoshida M, Akazawa K, Saito Y, Akagi S, Ohno Y, Kondo M, Miura D, Wada J, Ito H.

Int Heart J. 2019 May 30;60(3):728-735. doi: 10.1536/ihj.18-392. Epub 2019 May 17.

14.

Treat-and-repair strategy is a feasible therapeutic choice in adult patients with severe pulmonary arterial hypertension associated with a ventricular septal defect: case series.

Akagi S, Kasahara S, Sarashina T, Nakamura K, Ito H.

Eur Heart J Case Rep. 2018 Mar 22;2(2):yty033. doi: 10.1093/ehjcr/yty033. eCollection 2018 Jun.

15.

The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.

Ejiri K, Miyoshi T, Nakamura K, Sakuragi S, Munemasa M, Namba S, Takaishi A, Ito H.

BMJ Open. 2019 Mar 30;9(3):e026590. doi: 10.1136/bmjopen-2018-026590. Erratum in: BMJ Open. 2019 Jun 1;9(5):e026590corr1.

16.

Role of smooth muscle cell p53 in pulmonary arterial hypertension.

Wakasugi T, Shimizu I, Yoshida Y, Hayashi Y, Ikegami R, Suda M, Katsuumi G, Nakao M, Hoyano M, Kashimura T, Nakamura K, Ito H, Nojiri T, Soga T, Minamino T.

PLoS One. 2019 Feb 26;14(2):e0212889. doi: 10.1371/journal.pone.0212889. eCollection 2019.

17.

Combination of Renal Angioplasty and Angiotensin-converting-enzyme Inhibitor Can Reduce Proteinuria in Patients with Bilateral Renal Artery Disease.

Toda H, Uchida HA, Nakamura K, Takeuchi H, Kinomura M, Nakagawa K, Watanabe A, Miyoshi T, Nishii N, Morita H, Wada J, Ito H.

Intern Med. 2019 Jul 1;58(13):1917-1922. doi: 10.2169/internalmedicine.2076-18. Epub 2019 Feb 25.

18.

Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.

Kuroda K, Akagi S, Nakamura K, Sarashina T, Ejiri K, Ito H.

Heart Lung Circ. 2019 Feb 7. pii: S1443-9506(19)30048-4. doi: 10.1016/j.hlc.2019.01.013. [Epub ahead of print]

PMID:
30773322
19.

Decrease in oxidized high-density lipoprotein is associated with slowed progression of coronary artery calcification: Subanalysis of a prospective multicenter study.

Miki T, Miyoshi T, Kotani K, Kohno K, Asonuma H, Sakuragi S, Koyama Y, Nakamura K, Ito H.

Atherosclerosis. 2019 Apr;283:1-6. doi: 10.1016/j.atherosclerosis.2019.01.032. Epub 2019 Feb 1.

PMID:
30769272
20.

The optimal amount of salt intake.

Nakamura K, Miyoshi T.

Hypertens Res. 2019 May;42(5):752-753. doi: 10.1038/s41440-019-0225-7. Epub 2019 Feb 14. No abstract available.

PMID:
30765877

Supplemental Content

Loading ...
Support Center